Sarepta Therapeutics, Inc.
No SEC Form 4 filings for $SRPT in the last 30 days.
State Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.
Sarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.
Sarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.
Over the past 7 days, alphai's AI scored 6 news stories mentioning SRPT (Sarepta Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 1 bearish.
Recent SRPT coverage spans financial news, earnings and corporate actions.
SRPT receives a fresh 13G disclosure of large institutional beneficial ownership, potentially informing governance and takeover-readiness narratives.
Guidance narrowing plus shifted clinical timelines changes the near-term revenue and catalyst calendar for SRPT.
CEO transition arrives amid Elevidys safety overhang and confirmatory-approval risk for Amondys 45 and Vyondys 53, making near-term execution and FDA outcomes central to the stock.
Near-term trading should hinge on the guidance reset and Elevidys revenue trajectory, with pipeline timing risk into 1Q27 data.
A new CEO appointment can change near-term execution priorities, but the article provides no operational or financial targets.
alphai scores every news story that mentions SRPT with an AI model for sentiment and relevance, and aggregates insider trades from Sarepta Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
State Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.
2 min readSarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.
7 min readSarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.
5 min readSarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.
7 min readSarepta Therapeutics (NASDAQ:SRPT) said it will appoint Michael Severino, M.D., as chief executive officer effective July 28, 2026. The company said Severino previously served as CEO of Tessera Therapeutics and will join Sarepta’s board. The change may affect company strategy and leadership going forward.
2 min readSarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments – New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, b
6 min readSarepta Therapeutics said Michael Severino will become CEO effective July 28, replacing Doug Ingram, who plans to retire. Severino previously led development roles at AbbVie and Amgen and ran Tessera Therapeutics. The change comes as Sarepta faces Elevidys trial and FDA-related setbacks and declining gene-therapy sales. Sarepta shares were above $158 in June 2024 and trade around $16 now.
5 min readSarepta Therapeutics named Michael Severino CEO, replacing Doug Ingram, who stepped down for personal reasons and will advise until year-end. Ingram cited family DM1 diagnoses. Severino previously led Tessera and held senior roles at AbbVie and Amgen. The article notes prior setbacks, including Elevidys liver-toxicity reports and failed Vyondys 53 and Amondys 45 trials.
5 min readSarepta Therapeutics (SRPT) appointed Michael Severino, M.D., as CEO effective July 28, 2026, also adding him to the board. He succeeds Doug Ingram, retiring and staying as an adviser through year-end. Severino previously led Tessera Therapeutics and held senior roles at AbbVie. SRPT shares closed at $15.68 and were up in pre-market to $16.50.
2 min readSarepta Therapeutics appointed Michael Severino to replace outgoing CEO Doug Ingram, who will advise through end-2026. Morgan Stanley called the leadership change positive but kept an Equal Weight rating and a $25 price target, citing near-term Duchenne DMD challenges and upcoming regulatory and clinical milestones. SRPT shares were up about 4% at writing.
4 min read
